Literature DB >> 24817598

Sample-size calculation and reestimation for a semiparametric analysis of recurrent event data taking robust standard errors into account.

Katharina Ingel1, Antje Jahn-Eimermacher.   

Abstract

In some clinical trials, the repeated occurrence of the same type of event is of primary interest and the Andersen-Gill model has been proposed to analyze recurrent event data. Existing methods to determine the required sample size for an Andersen-Gill analysis rely on the strong assumption that all heterogeneity in the individuals' risk to experience events can be explained by known covariates. In practice, however, this assumption might be violated due to unknown or unmeasured covariates affecting the time to events. In these situations, the use of a robust variance estimate in calculating the test statistic is highly recommended to assure the type I error rate, but this will in turn decrease the actual power of the trial. In this article, we derive a new sample-size formula to reach the desired power even in the presence of unexplained heterogeneity. The formula is based on an inflation factor that considers the degree of heterogeneity and characteristics of the robust variance estimate. Nevertheless, in the planning phase of a trial there will usually be some uncertainty about the size of the inflation factor. Therefore, we propose an internal pilot study design to reestimate the inflation factor during the study and adjust the sample size accordingly. In a simulation study, the performance and validity of this design with respect to type I error rate and power are proven. Our method is applied to the HepaTel trial evaluating a new intervention for patients with cirrhosis of the liver.
© 2014 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  Andersen-Gill model; Inflation factor; Internal pilot study; Recurrent event data; Sample-size determination

Mesh:

Year:  2014        PMID: 24817598     DOI: 10.1002/bimj.201300090

Source DB:  PubMed          Journal:  Biom J        ISSN: 0323-3847            Impact factor:   2.207


  3 in total

1.  Time-to-first-event versus recurrent-event analysis: points to consider for selecting a meaningful analysis strategy in clinical trials with composite endpoints.

Authors:  Geraldine Rauch; Meinhard Kieser; Harald Binder; Antoni Bayes-Genis; Antje Jahn-Eimermacher
Journal:  Clin Res Cardiol       Date:  2018-02-16       Impact factor: 5.460

2.  A longitudinal observational study of back pain incidence, risk factors and occupational physical activity in Swedish marine trainees.

Authors:  Andreas Monnier; Helena Larsson; Håkan Nero; Mats Djupsjöbacka; Björn O Äng
Journal:  BMJ Open       Date:  2019-05-14       Impact factor: 2.692

3.  A DAG-based comparison of interventional effect underestimation between composite endpoint and multi-state analysis in cardiovascular trials.

Authors:  Antje Jahn-Eimermacher; Katharina Ingel; Stella Preussler; Antoni Bayes-Genis; Harald Binder
Journal:  BMC Med Res Methodol       Date:  2017-07-04       Impact factor: 4.615

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.